EGF and myeloid sarcoma: In the test cohort, plasma EGF and MIP-1β/CCL4 statistically differed in both classification groups (p<0.0001 and p = 0.0002, respectively); in the validation cohort, both analytes showed a trend (p = 0.06) to be at lower concentrations in the plasma of progressive patients (SP-MS and PP-MS) than in RR-MS patients (Table 3).